THE SILENT ENEMY FROM THE FIST - VIKING DISEASE
Keywords:
Dipitren's contracture, Viking's disease, clinical picture, diagnosis, therapy
Abstract
Dupuytren's contracture (DK) is a progressive idiopathic fibrosis of the superficial palmar fascia caused by changes in the palmar aponeurosis, resulting in flexion contracture of the fingers with inability to extend the fingers. The disease, also called Viking's disease, is present in 8% of the world's population, more common in men, and heredity, which shows variable expression, plays an important role in its etiology. The pathogenesis of DK is still unclear, and involves the formation of collagen nodules that progress into fibrous bands at the places of greatest pressure between the dermis and fascia. The diagnosis is established only by clinical examination, and the treatment can be conservative and surgical. Conservative treatment is reserved for patients with milder symptoms and no finger contracture, while surgical treatment is the gold standard in the therapy of people in whom the resulting contracture limits the function of the hand and/or flexion of the proximal interphalangeal joint by ≥15º and/or the metacarpophalangeal joint by ≥30º. The aim of this paper is to present the current findings related to DK.
References
1. Mitrović V. Dupuytrenova kontraktura – bolest Vikinga u suvremenom svijetu. Medicina fluminensis. 2023; 59(3): 229-40. doi: 10.21860/medflum2023_306340.
2. Elliot D. The early history of Dupuytren’s disease. Hand Clin. 1999;15(1):1-v.
3. Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. doi: 10.1186/s13018-020-01999-7.
4. Ng M, Lawson DJ, Winney B, Furniss D. Is Dupuytren’s disease really a ‘disease of the Vikings’?. J Hand Surg Eur Vol. 2020;45:273-79. doi:10.1177/1753193419882851.
5. Ng M, Thakkar D, Southam L, Werker P, Ophoff R, Becker K et al. A genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. Am J Hum Genet. 2017;101:417-27. doi:10.1016/j.ajhg.2017.08.006.
6. Todorović Z, Jovanović B, Stoiljković G. Dipitrenova kontraktura – naša iskustva. Apollinem medicum et aesculapium. 2012; 10(3):12-15.
7. Nikolić J, Janjić Z, Momčilovć D, Ninković S, Harhai V. Plantarna fibromatoza i Dupuytren-ova kontraktura kod adolescenta. Vojnosanit Pregl. 2011; 68(10):886-90. doi: 10.2298/VSP1110886N.
8. Fernando JJ, Fowler C, Graham T, Terry K, Grocott P, Sandford F. Pre-operative hand therapy management of Dupuytren's disease: A systematic review. Hand Ther. 2024;29(2):52-61. doi: 10.1177/17589983241227162.
9. Dutta A, Jayasinghe G, Deore S, Wahed K, Bhan K, Bakti N, et al. Dupuytren’s contracture—current concepts. J Clin Orthop Trauma. 2020;11(4):590-96. doi: 10.1016/j.jcot.2020.03.026.
10. Walthall J, Anand P, Rehman UH. Dupuytren Contracture. [Updated 2023 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526074/
11. Larocerie-Salgado J, Davidson J, Fenton P. Nonoperative Treatment of Dupuytren's Contracture: The Use of Ultrasound Imaging to Assess Efficacy. J Hand Microsurg. 2024;16(1):100003. doi:10.1055/s-0042-1748780
12. Lambi AG, Popoff SN, Benhaim P, Barbe MF. Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies. J Hand Surg Am. 2023;48(8):810-21. doi:10.1016/j.jhsa.2023.02.003
13. Park JW, Kim ST, Lee KS, Gong HS. Vitamin D status in Dupuytren’s disease: Association with clinical status and vitamin D receptor expression. J Plast Reconstr Aesthet Surg. 2022; 75:1916-22. doi:10.1016/j.bjps.2022.01.012.
14. Yildiz S, Karacaoğlu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004;24(1):26-29. doi:10.1002/micr.10198.
15. Davis SM, Chang EY. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021;7(4):63-67. doi: 10.22551/2020.29.0704.10175.
16. National Institute for Health and Care Excellence [Internet]. Nice: Radiation therapy for early Dupuytren’s disease. c2023 [cited 2021 Mar 8]. Available from: https://www.nice.org.uk/guidance/ipg573/resources/radiation-therapy-for-early-dupuytrens-disease-pdf-1899872106511813.
17. Reuttermann M, Hermann MR, Khatib Chatidi K, Werker PMN. Dupuytren’s Disease - Etiology and Treatment. Dtsch Arztebl Int. 2021;19:781-88. doi:10.3238/arztebl.m2021.0325.
18. Kuboi T, Tajika T, Endo F, Goto W, Nakajima I, Hasegawa S, et al. Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease. Prog Rehabil Med. 2021;6:20210023. doi: 10.2490/prm.20210023.
19. Warwick D, Arner M, Pajardi G, Szabo Z, Masmejean EH, Fores J et al. Collagenase clostridium histolyticum in patients with Duppuytren’s contracture: results from POINT X, an open label study of clinical and patient reported outcomes. J Hand Surg Eur. 2015;40:124-32. doi:10.1177/1753193413519926.
20. Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM et al. Efficacy and safety of concurrent colla¬genase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57-64. doi:10.1016/j.jhsa.2013.10.002.
21. Obed D, Salim M, Schlottmann F, Bingoel AS, Panayi AC, Dastagir K et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciotomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23:939. doi:10.1186/s12891-022-05894-6.
22. Dias J, Arundel C, Tharmanathan P, Keding A, Welch C, Corbacho B et al. Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial. Trials. 2021;22(1):671. doi:10.1186/s13063-021-05595-w.
23. Żyluk A. Dupuytren’s disease – what’s new: a review. Pol Przegl Chir. 2023; 95(6): 53-61. https://doi.org/10.5604/01.3001.0016.0058.
24. Almadani Y, Vorstenbosch J, Efanov JI, Xu L. Dupuytren’s Disease: an Outcomes-Focused Update. Sermin Plast Surg. 2021;35:216-22. doi:10.1055/s-0041-1731631.
25. Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017; 74(1): 19–23. doi: 10.2298/VSP150331103S.
26. Dias JJ, Aziz S. Fasciectomy for Dupuytren Contracture. Hand Clinics. 2018;34:351-66. doi:10.1016/j.hcl.2018.04.002.
27. Kan HJ, Verrijp FW, Hovious SER, van Nieuwenhoven CA, Group DD, Selles RW. Correction: Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2019;14(4):e0216313. doi:10.1371/journal.pone.0216313.
28. Van Nuffel M, Meulyzer C, Vrancken C, Van den Kerckhove E, De Smet L, Degreef I. Treatment practice for Dupuytren disease in Belgium before 2020: results from an online survey. Acta Orthop Belg. 2022;88(2):399-409. doi:10.52628/88.2.9764.
29. Taheri P, Salek N, Mousavi M, Maghroori R. The effect of Shock Wave Therapy on Improving the Symptoms and Function of Patients with Dupuytren’s Contracture. Adv Biomed Res. 2022; 11:3. doi:10.4103/abr.abr_155_21.
30. Aglen T. Matre KH, Lind C, Selles RW, Assmus J, Taule T. Hand therapy or not following collagenase treatment for Dupuytren’s contracture? Protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2019;20:387. doi:10.1186/s12891-019-2712-z.
2. Elliot D. The early history of Dupuytren’s disease. Hand Clin. 1999;15(1):1-v.
3. Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. doi: 10.1186/s13018-020-01999-7.
4. Ng M, Lawson DJ, Winney B, Furniss D. Is Dupuytren’s disease really a ‘disease of the Vikings’?. J Hand Surg Eur Vol. 2020;45:273-79. doi:10.1177/1753193419882851.
5. Ng M, Thakkar D, Southam L, Werker P, Ophoff R, Becker K et al. A genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. Am J Hum Genet. 2017;101:417-27. doi:10.1016/j.ajhg.2017.08.006.
6. Todorović Z, Jovanović B, Stoiljković G. Dipitrenova kontraktura – naša iskustva. Apollinem medicum et aesculapium. 2012; 10(3):12-15.
7. Nikolić J, Janjić Z, Momčilovć D, Ninković S, Harhai V. Plantarna fibromatoza i Dupuytren-ova kontraktura kod adolescenta. Vojnosanit Pregl. 2011; 68(10):886-90. doi: 10.2298/VSP1110886N.
8. Fernando JJ, Fowler C, Graham T, Terry K, Grocott P, Sandford F. Pre-operative hand therapy management of Dupuytren's disease: A systematic review. Hand Ther. 2024;29(2):52-61. doi: 10.1177/17589983241227162.
9. Dutta A, Jayasinghe G, Deore S, Wahed K, Bhan K, Bakti N, et al. Dupuytren’s contracture—current concepts. J Clin Orthop Trauma. 2020;11(4):590-96. doi: 10.1016/j.jcot.2020.03.026.
10. Walthall J, Anand P, Rehman UH. Dupuytren Contracture. [Updated 2023 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526074/
11. Larocerie-Salgado J, Davidson J, Fenton P. Nonoperative Treatment of Dupuytren's Contracture: The Use of Ultrasound Imaging to Assess Efficacy. J Hand Microsurg. 2024;16(1):100003. doi:10.1055/s-0042-1748780
12. Lambi AG, Popoff SN, Benhaim P, Barbe MF. Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies. J Hand Surg Am. 2023;48(8):810-21. doi:10.1016/j.jhsa.2023.02.003
13. Park JW, Kim ST, Lee KS, Gong HS. Vitamin D status in Dupuytren’s disease: Association with clinical status and vitamin D receptor expression. J Plast Reconstr Aesthet Surg. 2022; 75:1916-22. doi:10.1016/j.bjps.2022.01.012.
14. Yildiz S, Karacaoğlu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004;24(1):26-29. doi:10.1002/micr.10198.
15. Davis SM, Chang EY. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021;7(4):63-67. doi: 10.22551/2020.29.0704.10175.
16. National Institute for Health and Care Excellence [Internet]. Nice: Radiation therapy for early Dupuytren’s disease. c2023 [cited 2021 Mar 8]. Available from: https://www.nice.org.uk/guidance/ipg573/resources/radiation-therapy-for-early-dupuytrens-disease-pdf-1899872106511813.
17. Reuttermann M, Hermann MR, Khatib Chatidi K, Werker PMN. Dupuytren’s Disease - Etiology and Treatment. Dtsch Arztebl Int. 2021;19:781-88. doi:10.3238/arztebl.m2021.0325.
18. Kuboi T, Tajika T, Endo F, Goto W, Nakajima I, Hasegawa S, et al. Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease. Prog Rehabil Med. 2021;6:20210023. doi: 10.2490/prm.20210023.
19. Warwick D, Arner M, Pajardi G, Szabo Z, Masmejean EH, Fores J et al. Collagenase clostridium histolyticum in patients with Duppuytren’s contracture: results from POINT X, an open label study of clinical and patient reported outcomes. J Hand Surg Eur. 2015;40:124-32. doi:10.1177/1753193413519926.
20. Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM et al. Efficacy and safety of concurrent colla¬genase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57-64. doi:10.1016/j.jhsa.2013.10.002.
21. Obed D, Salim M, Schlottmann F, Bingoel AS, Panayi AC, Dastagir K et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciotomy in the treatment of Dupuytren’s contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23:939. doi:10.1186/s12891-022-05894-6.
22. Dias J, Arundel C, Tharmanathan P, Keding A, Welch C, Corbacho B et al. Dupuytren’s interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial. Trials. 2021;22(1):671. doi:10.1186/s13063-021-05595-w.
23. Żyluk A. Dupuytren’s disease – what’s new: a review. Pol Przegl Chir. 2023; 95(6): 53-61. https://doi.org/10.5604/01.3001.0016.0058.
24. Almadani Y, Vorstenbosch J, Efanov JI, Xu L. Dupuytren’s Disease: an Outcomes-Focused Update. Sermin Plast Surg. 2021;35:216-22. doi:10.1055/s-0041-1731631.
25. Stepić N, Končar J, Rajović M. The influence of Dupuytren's disease fingers contracture degree on surgical treatment outcome. Vojnosanit Pregl. 2017; 74(1): 19–23. doi: 10.2298/VSP150331103S.
26. Dias JJ, Aziz S. Fasciectomy for Dupuytren Contracture. Hand Clinics. 2018;34:351-66. doi:10.1016/j.hcl.2018.04.002.
27. Kan HJ, Verrijp FW, Hovious SER, van Nieuwenhoven CA, Group DD, Selles RW. Correction: Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2019;14(4):e0216313. doi:10.1371/journal.pone.0216313.
28. Van Nuffel M, Meulyzer C, Vrancken C, Van den Kerckhove E, De Smet L, Degreef I. Treatment practice for Dupuytren disease in Belgium before 2020: results from an online survey. Acta Orthop Belg. 2022;88(2):399-409. doi:10.52628/88.2.9764.
29. Taheri P, Salek N, Mousavi M, Maghroori R. The effect of Shock Wave Therapy on Improving the Symptoms and Function of Patients with Dupuytren’s Contracture. Adv Biomed Res. 2022; 11:3. doi:10.4103/abr.abr_155_21.
30. Aglen T. Matre KH, Lind C, Selles RW, Assmus J, Taule T. Hand therapy or not following collagenase treatment for Dupuytren’s contracture? Protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2019;20:387. doi:10.1186/s12891-019-2712-z.
Published
2025/01/23
Section
Članci
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).